Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

Luis A Diaz, Kai-Keen Shiu, Tae-Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis Punt, Denis Smith, Rocio Garcia-Carbonero, Manuel Benavides, Peter Gibbs, Christelle de la Fourchardiere, Fernando Rivera, Elena Elez, Dung T Le, Takayuki Yoshino, Wen Yan Zhong, David Fogelman, Patricia Marinello, Thierry Andre, KEYNOTE-177 Investigators

Health Services Research Unit (HSRU)

Memorial Sloan-Kettering Cancer Center
Great Ormond Street Hospital for Children NHS Trust
University of Ulsan
Herlev and Gentofte Hospital
University Hospital of Southern Denmark
Utrecht University of Applied Sciences
Bordeaux University Hospital
University Hospitals Leuven, Belgium.
IBIMA Hospital Universitario Regional y Virgen de la Victoria
Western Health
Léon Bérard Center
Hospital Universitario Marques de Valdecilla
Vall d'Hebron Institute of Oncology
Johns Hopkins University
National Cancer Center Hospital East
MSD China
Merck Frosst
Université Paris 1 Panthéon-Sorbonne

Research output: Contribution to journal › Article › peer-review

273 Citations (Scopus)

Sort by
Weight
Alphabetically

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

Fingerprint

Medicine & Life Sciences